Also known as: Iovance Biotherapeutics
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company developing and commercializing autologous tumor-infiltrating lymphocyte cell therapies for metastatic melanoma and other solid tumors. The company was incorporated in 2007 and is headquartered in San Carlos, California.
Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.
Iovance reported real-world data suggesting Amtagvi may have a best in class profile in advanced melanoma. The company posted $263.5 million in annual sales after 2024 approval, while pursuing broader use and facing regulatory and logistics risks.
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
